Continuum Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.3K Buy
+55
New +$12K ﹤0.01% 1172
2025
Q2
Sell
-55
Closed -$6.83K 1024
2025
Q1
$6.83K Sell
55
-3
-5% -$391 ﹤0.01% 1060
2024
Q4
$7.14K Sell
58
-3
-5% -$354 ﹤0.01% 1065
2024
Q3
$7.58K Hold
61
﹤0.01% 1066
2024
Q2
$6.51K Hold
61
﹤0.01% 1036
2024
Q1
$6.9K Buy
+61
New +$7.47K ﹤0.01% 1021

Other funds holding JAZZ

Continuum Advisory's JAZZ Position: Q2 2026 in Review

Continuum Advisory opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 55 shares worth $13.3K. The stake represents ﹤0.01% of the portfolio and ranks #1172 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in JAZZ as recently as Q1 2025.

Continuum Advisory first reported a position in JAZZ in Q1 2024 and has held it in 6 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Continuum Advisory held 55 shares of Jazz Pharmaceuticals worth $13.3K as of Q2 2026.
  • Jazz Pharmaceuticals was a new Continuum Advisory position in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1172 holding.
  • Continuum Advisory first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.